MedTrace Logo

Beta Glucan and Acetate Production

NCT03714646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-01-13

No results posted yet for this study

Summary

Based on our hypothesis that orally administered resistant starch and beta glucan will be fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects on human substrate and energy metabolism, we aim to address the following primary objective:

To investigate the effects of an acute administration of inulin/beta glucan in combination with resistant starch on fecal and plasma acetate, as well as on fasting and postprandial substrate and energy metabolism in lean normoglycemic men and obese, prediabetic men.

Conditions

Interventions

DIETARY_SUPPLEMENT

beta glucan and resistant starch

12g per day the day before the CID Resistant starch 7.5 g

DIETARY_SUPPLEMENT

Placebo

isocaloric maltodextrin before the CID

DIETARY_SUPPLEMENT

beta gluten

12 g beta gluten there day before the CID

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2019-05-10
Completion
2019-05-10

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714646 on ClinicalTrials.gov